Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: Initiate treatment early or wait for the catheterization laboratory?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Treatment of patients with acute coronary syndromes (ACS) incorporates several approaches to reverse or mitigate the thrombus, which invariably is at the center of the pathophysiologic process of ACS. Pharmacologic and mechanical strategies are designed to prevent death, reduce myocardial necrosis, and stabilize the plaque to prevent later sequelae. Conventional antithrombotic therapy includes antiplatelet and anticoagulant drugs. Medications that inhibit the platelet glycoprotein IIb/IIIa receptor have been shown to be especially efficacious in the treatment of ACS. Recent clinical trials have validated a strategy of aggressive revascularization, particularly catheter-based percutaneous procedures. This review summarizes new trial results and provides a working algorithm for care of the patient with ACS.
- Kong DF, Blazing MA, O’Connor CM: The health care burden of unstable angina. Card Clin 1999, 17:247–261. CrossRef
- Libby P: Multiple mechanisms of thrombosis complicating atherosclerotic plaques. Clin Cardiol 2000, 23:VI3-VI7. CrossRef
- Theroux P, Ouimet H, McCans J, et al.: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988, 319:1105–1111. CrossRef
- Antiplatelet Trialists’ Collaboration: Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994, 308:81–106.
- oler A, Whooley MA, oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996, 276:811–815. CrossRef
- Yusuf S: The CURE Trial results. Presented at the Annual Scientific Sessions of the American College of Cardiology. orlando, FL: March 2001.
- Wagner CC, Mascelli MA, Neblock S, et al.: Analysis of GP IIb/ IIIa receptor number and quantification of c7E3 binding to human platelets. Blood 1996, 88:907–914.
- Chew DP, Moliterno DJ: A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Card 2000, 36:2028–2035. CrossRef
- Bhatt DL, Topol EG: Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000, 284:1549–1558. This is an exceptional review article highlighting the importance of GP IIb/IIIa inhibitors in acute coronary syndromes, with a comprehensive summary of trials with GP IIb/IIIa in PCI and in the medical management of UA/NQMI. Includes dosing and adverse effects of GP IIb/IIIa and recommendations on proper treatment strategy. CrossRef
- The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994, 330:956–961. CrossRef
- The EPILoG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997, 336:1689–1696. CrossRef
- The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998, 352:87–92. CrossRef
- The IMPACT Investigators:Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997, 349:1422–1428. CrossRef
- The ESPRIT Investigators: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000, 356:2037–2044. CrossRef
- Topol EJ, Moliterno DJ, Herrmann HC, et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001, 344:1879–1887. CrossRef
- Myler RK, Shas RE, Stertzer SH, et al.: Unstable angina and coronary angioplasty. Circulation 1990, 82(suppl II):II88-II95.
- The TIMI IIIB Investigators: Effects of tissue plasminogen activator and comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation 1994, 89:1545–1556.
- Boden WE, O’Rourke RA, Crawford MH, et al. for the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators: outcomes in patients with acute non-Q-wave MI randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998, 338:1785–1792. CrossRef
- Yusuf S, Flather M, Pogue J, et al.: Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation: oASIS (organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet 1998, 352:507–514. CrossRef
- Cannon CP, Weintraub WS, Demopoulos LA, et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001, 344:1879–1894. CrossRef
- FRISC II Investigators: Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 1999, 354:708–715. CrossRef
- Wallentin L, Lagerqvist B, Husted S, et al.: outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomized trial. Lancet 2000, 356:9–16. CrossRef
- The PRISM Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998, 338:1498–1505. CrossRef
- The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS) Study Investigators: Inhibition of the platelet Glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998, 339:436–443. CrossRef
- The PURSUIT Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998, 339:436–443. CrossRef
- Harrington RA, Lincoff MA, Berdan LG, et al.: Maintenance of clinical benefit at six-months in patients treated with the platelet Glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event. Circulation 1998, 98:I359.
- Kleiman NS, Lincoff AM, Flaker GC, et al.: Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes: PURSUIT Investigators. Circulation 2000, 101:751–757.
- The PARAGoN Investigators: International, randomized, controlled trial of lamifiban (a platelet Glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998, 97:2386–2395.
- The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997, 349:1429–1435. CrossRef
- Boersma E, Akkerhuis M, Theroux P, et al.: Platelet Glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999, 100:2045–2048. This article elaborates the benefits of GP IIb/IIIa in the period before and immediately after PCI. First review to illustrate the importance of GP IIb/IIIa as a bridge to invasive strategies.
- The GUSTo IV-ACS Investigators: Effect of glycoprotein IIb/ IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTo IV-ACS randomised trial. Lancet 2001, 357:1915–1924. CrossRef
- Hamm CW, Braunwald E: A classification of unstable angina revisited. Circulation 2000, 102:118–122.
- Antman EM, Cohen M, Bernink PJLM: The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000, 284:835–842. CrossRef
- Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guidelines for unstable angina. J Am Coll Cardiol 2000, 36:970–1062. CrossRef
- Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: Initiate treatment early or wait for the catheterization laboratory?
Current Cardiology Reports
Volume 3, Issue 5 , pp 355-361
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links